Lim Kyung-Min, Kwon Jae-Hyuk, Kim Keunyoung, Noh Ji-Yoon, Kang Seojin, Park Jung-Min, Lee Moo-Yeol, Bae Ok-Nam, Chung Jin-Ho
College of Pharmacy, Ewha Womans University, Seoul, Korea.
Br J Pharmacol. 2014 Sep;171(18):4300-10. doi: 10.1111/bph.12804.
Dysregulated tonic tension and calcium sensitization in blood vessels has frequently been observed in many cardiovascular diseases. Despite a huge therapeutic potential, little is known about natural products targeting tonic tension and calcium sensitization.
We screened natural products for inhibitory effects on vasoconstriction using the rat isolated thoracic aorta and found that an anthraquinone derivative, emodin, attenuated tonic tension. Organ bath system, primary vascular smooth muscle cells, confocal microscopy and Western blot analysis were employed to demonstrate the suppressive effects of emodin on PKCδ-mediated myosin phosphatase inhibition.
Emodin, an active ingredient of Polygonum multiflorum extract, inhibited phenylephrine-induced vasoconstriction in rat isolated thoracic aorta, and inhibited vasoconstriction induced by 5-HT and endothelin-1. It also generally suppressed vasoconstrictions mediated by voltage-operated, store-operated calcium channels and intracellular calcium store. However, emodin did not affect agonist-induced calcium increases in primary smooth muscle cells. In contrast, post-treatment with emodin following phenylephrine stimulation potently suppressed tonic tension in rat aortic rings. Western blot analysis revealed that emodin inhibited phenylephrine-induced phospho-myosin light chain (pMLC) and the phosphorylation of myosin-targeting subunit and C-kinase-activated protein phosphatase-1 inhibitor (CPI-17). This was mediated by selective inhibition of PKCδ, whereas PKCα was not involved.
Emodin attenuates tonic tension through the blockade of PKCδ and CPI-17-mediated MLC-phosphatase inhibition. This new mode of action for the suppression of tonic tension and structural insights into PKCδ inhibition revealed by emodin may provide new information for the development of modulators of tonic tension and for the treatment of hypertension.
在许多心血管疾病中,常观察到血管中张力调节失调和钙敏化现象。尽管具有巨大的治疗潜力,但针对张力调节和钙敏化的天然产物却知之甚少。
我们利用大鼠离体胸主动脉筛选对血管收缩有抑制作用的天然产物,发现一种蒽醌衍生物大黄素可减弱张力。采用器官浴系统、原代血管平滑肌细胞、共聚焦显微镜和蛋白质印迹分析来证明大黄素对蛋白激酶Cδ(PKCδ)介导的肌球蛋白磷酸酶抑制的抑制作用。
大黄素是何首乌提取物的一种活性成分,可抑制苯肾上腺素诱导的大鼠离体胸主动脉血管收缩,并抑制5-羟色胺和内皮素-1诱导的血管收缩。它还普遍抑制由电压门控、储存操纵性钙通道和细胞内钙库介导的血管收缩。然而,大黄素并不影响激动剂诱导的原代平滑肌细胞内钙增加。相反,在苯肾上腺素刺激后用大黄素进行后处理可有效抑制大鼠主动脉环的张力。蛋白质印迹分析显示,大黄素可抑制苯肾上腺素诱导的磷酸化肌球蛋白轻链(pMLC)以及肌球蛋白靶向亚基和C激酶激活的蛋白磷酸酶-1抑制剂(CPI-17)的磷酸化。这是通过对PKCδ的选择性抑制介导的,而PKCα未参与其中。
大黄素通过阻断PKCδ和CPI-17介导的肌球蛋白轻链磷酸酶抑制来减弱张力。大黄素揭示的这种抑制张力的新作用模式以及对PKCδ抑制的结构见解可能为张力调节剂的开发和高血压治疗提供新信息。